{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:24:57Z","timestamp":1794605097776,"version":"4.9.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy is limited by cytokine release syndrome (CRS) and neurotoxicity (NT). We sought to use once-daily prophylactic anakinra, an interleukin-1 (IL-1) receptor antagonist, to prevent CRS\/NT that would require hospitalization (grade \u22652) in patients receiving axicabtagene ciloleucel for large-cell lymphoma, with the goal of facilitating outpatient therapy and management. Our study, in line with others, demonstrates that once-daily prophylactic anakinra is insufficient to prevent the development of toxicities that would require hospitalization in most patients. As part of the initial study design, we prospectively incorporated single-cell RNA sequencing to gain insight into the molecular immune signaling associated with breakthrough CRS and NT despite anakinra prophylaxis. In patients who developed breakthrough CRS or NT, we found that interferon gamma (IFN-\u03b3) pathways and ligand-receptor activities were significantly enriched, as were cytokine levels of IFN-\u03b3 and CXCL10 in CD14+ monocytes. This correlated with increased IFN-\u03b3 and other cytokines in the peripheral blood. In infused CAR-T products, IL-4 and IL-10 anti-inflammatory pathways were negatively associated with grade \u22652 toxicities, regardless of anakinra treatment. These data identify IFN-\u03b3 as a potential key mechanism in CAR-T\u2013associated toxicities, which is not inhibited by anakinra but may be otherwise targetable. This trial was registered at www.ClinicalTrials.gov as #NCT04150913.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015161","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T22:05:26Z","timestamp":1739225126000},"page":"2122-2135","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma"],"prefix":"10.1182","volume":"9","author":[{"given":"Matthew J.","family":"Frigault","sequence":"first","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yao","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha R.","family":"Berger","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7915-5862","authenticated-orcid":false,"given":"Marc","family":"Wehrli","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M. E.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Horick","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-7305","authenticated-orcid":false,"given":"Charlotte E.","family":"Graham","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"},{"name":"4Dana-Farber Cancer Institute, Department of Hematology\/Oncology, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-0221","authenticated-orcid":false,"given":"Mark B.","family":"Leick","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej R.","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3943-6608","authenticated-orcid":false,"given":"P. Connor","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dolaher","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Katsis","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"},{"name":"4Dana-Farber Cancer Institute, Department of Hematology\/Oncology, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":false,"given":"Jennifer","family":"Crombie","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"},{"name":"4Dana-Farber Cancer Institute, Department of Hematology\/Oncology, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"},{"name":"4Dana-Farber Cancer Institute, Department of Hematology\/Oncology, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Cook","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trailor","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Cho","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Richard","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[{"name":"5Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Filosto","sequence":"additional","affiliation":[{"name":"5Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-0653","authenticated-orcid":false,"given":"Jenny","family":"Nater","sequence":"additional","affiliation":[{"name":"5Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-3135","authenticated-orcid":false,"given":"Nicholas J.","family":"Haradhvala","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"1Cellular Immunotherapy Program, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Cancer Program, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"1","key":"2025051308315375100_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025051308315375100_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025051308315375100_bib3","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity [abstract]","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025051308315375100_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"2025051308315375100_bib5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2025051308315375100_bib6","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"20","key":"2025051308315375100_bib7","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051308315375100_bib8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025051308315375100_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2025051308315375100_bib10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","article-title":"Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids","volume":"59","author":"Oluwole","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2025051308315375100_bib11","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025051308315375100_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"27","key":"2025051308315375100_bib13","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025051308315375100_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2025051308315375100_bib15","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"Sonmez","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"2","key":"2025051308315375100_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"6","key":"2025051308315375100_bib17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2025051308315375100_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2025051308315375100_bib19","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2025051308315375100_bib20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"2025051308315375100_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2025051308315375100_bib22","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"21","key":"2025051308315375100_bib23","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025051308315375100_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2016;128(11):1553]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051308315375100_bib25","first-page":"2826","article-title":"Phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025051308315375100_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2025051308315375100_bib27","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025051308315375100_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The International Harmonization Project for response criteria in lymphoma clinical trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2025051308315375100_bib29","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"2025051308315375100_bib30","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"6282","key":"2025051308315375100_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"2025051308315375100_bib32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"2025051308315375100_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ccell.2019.04.003","article-title":"Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation","volume":"35","author":"Segovia","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"2025051308315375100_bib34","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.4049\/jimmunol.174.9.5789","article-title":"Resistin, an adipokine with potent proinflammatory properties","volume":"174","author":"Bokarewa","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"2025051308315375100_bib35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.cmet.2014.01.013","article-title":"Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes","volume":"19","author":"Lee","year":"2014","journal-title":"Cell Metab"},{"key":"2025051308315375100_bib36","doi-asserted-by":"crossref","first-page":"699807","DOI":"10.3389\/fimmu.2021.699807","article-title":"Resistin, a novel host defense peptide of innate immunity","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2025051308315375100_bib37","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood-2021-146927","article-title":"A phase II trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025051308315375100_bib38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2025051308315375100_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025051308315375100_bib40","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"2025051308315375100_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2025051308315375100_bib42","doi-asserted-by":"crossref","first-page":"830061","DOI":"10.3389\/fimmu.2022.830061","article-title":"Resistin associated with cytokines and endothelial cell adhesion molecules is related to worse outcome in COVID-19","volume":"13","author":"Ebihara","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"2025051308315375100_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study","volume":"31","author":"Galea","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"2025051308315375100_bib44","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2122\/2371055\/blooda_adv-2024-015161-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2122\/2371055\/blooda_adv-2024-015161-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T12:32:04Z","timestamp":1747139524000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/9\/2122\/535555\/Single-cell-dynamics-of-breakthrough-toxicities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015161","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}